The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: A prospective cohort analysis

AIDS

Volumn 16, Issue 15, 2002, Pages

  Haubrich, Richard H ^a   Kemper, Carol A ^a   Hellmann, Nicholas S ^a   Keiser, Philip H ^a   Witt, Mallory D ^a   Forthal, Donald N ^a   Leedom, John ^a   Leibowitz, Matthew ^a   Whitcomb, Jeannette M ^a   Richman, Douglas ^a   McCutchan, J Allen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; Clinical trials; HIV 1; Hypersusceptibility; Non nucleoside reverse transcriptase inhibitor; Phenotypic resistance

Indexed keywords

ABACAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 18344409610     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200210180-00001     Document Type: Article

References (22)

1. Hirsch MS, Brun-Vezinet F, D'Aquila RT et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000, 283:2417-2426.
2. Clevenbergh P, Durant J, Halfon P et al. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antivir Ther 2000, 5:65-70.
3. Baxter JD, Mayers DL, Wentworth DN et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000, 14:F83-F93.
4. Haubrich R, Demeter L. International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr 2001, 26(Suppl 1):S51-S59.
5. Whitcomb J, Deeks S, Huang W et al. Reduced susceptibility to NRTI is associated with NNRTI hypersensitivity in virus from HIV-1-infected patients. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2000 [abstract 234].
6. Shulman N, Zolopa AR, Passaro D et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 2001, 15:1125-1132.
7. Petropoulos CJ, Parkin NT, Limoli KL et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000, 44:920-928.
8. Hellmann N, Johnson P, Petropoulos C, and the ViroLogic Research Laboratory. Validation of the performance characteristics of a novel, rapid phenotypic drug susceptibility assay, PhenoSense HIV. Antivir Ther 1999, 4(Suppl. 1):34.
9. Gulick RM, Hu XJ, Fiscus SA et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis 2000, 182:1375-1384.
10. Demeter LM, Hughes MD, Coombs RW et al. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med 2001, 135:954-964.
11. Phillips AN, Staszewski S, Weber R et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001, 286:2560-2567.
12. Marimoutou C, Chene G, Mercie P et al. Prognostic factors of combined viral load and CD4 cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. J Acquir Immune Defic Syndr 2001, 27:161-167.
13. DeGruttola V, Dix L, D'Aquila R et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000, 5:41-48.
14. Haubrich R, Kemper C, Witt M et al. Reproducibility of an HIV phenotype resistance assay in clinical practice. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [abstract 417].
15. Mathews C, Haubrich R, Barber E, Havlir D. Patterns and prognostic implications of prior antiretroviral therapy (ART) at UCSD Owen Clinic: 1996-1999. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2000 [abstract 762].
16. Deeks SG, Hecht FM, Swanson M et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999, 13:F35-F43.
17. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81-87.
18. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999, 353:863-868.
19. Wit FW, van Leeuwen R, Weverling GJ et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999, 179:790-798.
20. Knobel H, Guelar A, Carmona A et al. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDS 2001, 15:193-199.
21. Bini T, Testa L, Chiesa E et al. Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000, 24:115-122.
22. Albrecht MA, Bosch RJ, Hammer SM et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001, 345:398-407.